Inflammatix secures $102M in financing

By LabPulse.com staff writers

March 16, 2021 -- Molecular diagnostics firm Inflammatix has secured $102 million in financing that it plans to use to commercialize its novel immune response diagnostics portfolio.

Inflammatix's diagnostics use machine-learning algorithms to track a patient's immune response to infections across multiple messenger RNA (mRNA) biomarkers, it said. The tests identify whether an infection is viral or bacterial and help clinicians gauge the risk of severe disease, including COVID-19, producing results in less than 30 minutes, according to the firm.

The funding was led by D1 Capital Partners, with participation from existing investors Northpond Ventures, Khosla Ventures, Think.Health, and OSF Healthcare Ventures.

Inflammatix secures $7.4M in BARDA funding
Molecular diagnostics firm Inflammatix has secured an additional $7.4 million in funding from the Biomedical Advanced Research and Development Authority...
Inflammatix gets $32M infusion for HostDx rapid POC tests
California startup Inflammatix has raised $32 million in series C financing, which it plans to use to move its HostDx rapid point-of-care (POC) tests...
Inflammatix scores BARDA contract for infection tests
Startup Inflammatix is set to get $6 million from the U.S. Biomedical Advanced Research and Development Authority (BARDA) and up to $72 million...
AACC: Inflammatix sepsis test wins Disruptive Technology contest
ANAHEIM, CA - A blood test for sepsis developed by California startup Inflammatix beat out products from two other companies to win the Disruptive Technology...

Copyright © 2021 LabPulse.com

Last Updated ls 3/16/2021 3:56:21 PM